...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Treatment of moderate to severe Alzheimer's disease: rationale and trial design.
【24h】

Treatment of moderate to severe Alzheimer's disease: rationale and trial design.

机译：中度至重度阿尔茨海默氏病的治疗：原理和试验设计。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Moderate to severe Alzheimer's disease (AD) is characterized by increasing cognitive, functional, and behavioural dysfunction that results in increased caregiver burden and, eventually, complete dependence. Despite its significance as a societal health problem, there are few treatment trials of cognitive enhancers or disease modifying agents for this stage of illness. Studies suggest the cholinesterase inhibitors, especially donepezil, may provide benefit. Several studies provide support for the use of the NMDA receptor antagonist memantine as monotherapy or added to a cholinesterase inhibitor for moderate to severe AD. While there are no published guidelines for the treatment of moderate to severe AD, these studies do provide guidance for recommendations for study design and outcome measures. Such studies are urgently needed.
机译：中度至重度阿尔茨海默氏病（AD）的特征是认知，功能和行为功能障碍增加，从而导致护理人员负担增加，并最终导致完全依赖。尽管它作为社会健康问题具有重要意义，但对于这一阶段的疾病，很少有认知增强剂或疾病改良剂的治疗试验。研究表明，胆碱酯酶抑制剂，尤其是多奈哌齐，可能会带来益处。多项研究为将NMDA受体拮抗剂美金刚作为单药治疗或加至胆碱酯酶抑制剂用于中度至重度AD提供了支持。尽管没有公开的中重度AD治疗指南，但这些研究确实为研究设计和结果测量的建议提供了指导。迫切需要这样的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号